Business Context and Reporting Period
Company: Myriad Genetics, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 1998
Business Overview: Myriad Genetics focuses on maintaining research and development programs, operating a genetic testing laboratory, and supporting collaborative research agreements. The company has been unprofitable since inception, relying on collaborative funding and genetic test sales (specifically BRACAnalysis for breast and ovarian cancer) for revenue.
Key Financial Metrics
| Metric | Three Months Ended Mar 31, 1998 | Nine Months Ended Mar 31, 1998 |
|---|---|---|
| Total Revenues | $5,689,093 | $16,702,487 |
| Net Loss | ($2,648,223) | ($6,708,645) |
| Net Loss Per Share | ($0.28) | ($0.72) |
| Cash and Cash Equivalents | $13,376,776 | $13,376,776 (Ending Balance) |
| Net Cash Used in Operating Activities | ($2,760,468) | ($5,113,061) |
| Accumulated Deficit | ($30,856,036) as of Mar 31, 1998 | |
| Notes Payable (Current) | $217,943 | N/A |
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased 107% to $5.69 million for the quarter and 117% to $16.70 million for the nine-month period compared to the prior year. This was driven by milestone payments and expanded research collaborations.
- Research Revenue: Increased $2.54 million for the quarter, primarily due to $1 million in milestone payments ($500k from Novartis, $500k from Schering) and increased funding from Schering.
- Genetic Testing Revenue: Rose to $566,689 for the quarter (up $409,111) due to the commercial launch and marketing of BRACAnalysis.
- Expense Increases:
- R&D Expenses: Increased to $5.46 million (quarter) due to expanded research activities, equipment purchases, and personnel hiring.
- Selling, General & Administrative (SG&A): Increased to $3.31 million (quarter) largely due to expanding the internal sales staff from 8 to 23 employees to support BRACAnalysis.
- Operating Loss: Narrowed to $3.43 million for the quarter from $3.98 million in the prior year, despite higher expenses, due to significant revenue growth.
Guidance, Outlook, and Risks
- Outlook: Management expects to incur losses for at least the next several years due to the expansion of R&D programs, staffing costs, and facility expansion. The company anticipates substantial sales and marketing expenses to build its genetic testing business.
- Liquidity: The company believes existing capital resources (including IPO proceeds and interest) are adequate to maintain operations for at least the next two years. It intends to raise additional funds when conditions are favorable.
- Collaborations: Key partnerships with Novartis, Bayer, and Schering provide funding and potential milestone payments. Recent milestones included the discovery of the CHD1 gene (Novartis) and MMAC1 gene (Schering).
- Risks and Contingencies:
- Legal Proceedings: Ongoing patent infringement litigation with OncorMed, Inc. regarding BRCA1 gene patents. The company is unable to estimate potential losses but believes the outcome will not materially affect its financial position.
- Market Risks: Intense competition in gene discovery, uncertainty regarding reimbursement from insurers, and the risk that genetic tests may not achieve commercial acceptance.
- Year 2000 Issue: Management determined the Y2K issue will not have a material effect on operations.
Investor Verification Checklist
- Legal Exposure: Verify the status and potential financial impact of the patent infringement lawsuits with OncorMed, Inc.
- Revenue Sustainability: Assess the reliance on milestone payments from collaborators (Novartis, Bayer, Schering) versus recurring revenue from genetic testing.
- Burn Rate: Monitor the rate of cash consumption in operating activities against the projected two-year runway.
- Commercialization: Track the adoption rates and reimbursement status of the BRACAnalysis and CardiaRisk tests.
- Debt Obligations: Review the terms and repayment schedule of the equipment financing facility.